Condition (MeSH)
IgA Deficiency
ClinicalTrials.gov lists 2 trials for IgA Deficiency or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with IgA Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did IgA Deficiency trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2001 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are IgA Deficiency trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Observational | 1 |
How many IgA Deficiency trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most IgA Deficiency trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
Which publications cover IgA Deficiency? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia. | Journal of clinical immunology | 2021 | Yes |
| Does OM-85 BV prophylaxis trigger autoimmunity in IgA deficient children? | International immunopharmacology | 2011 | Yes |
| Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. | Proceedings of the National Academy of Sciences of the United States of America | 1989 | Yes |
| A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). | Frontiers in immunology | 2019 | No |
| Ataxia-telangiectasia: Immunodeficiency and survival. | Clinical immunology (Orlando, Fla.) | 2017 | No |
Showing 5 of 8 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.